Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

for adult patients with relapsing-remitting multiple sclerosis. While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Sanofi’s (NASDAQ:SNY ... mostly unchanged from last year. RHHBY’s multiple sclerosis therapy Ocrevus, eye therapy Vabysmo, and hemophilia therapy Hemlibra drove the pharma expansion with ...

Despite advances in treatment, people with multiple sclerosis (MS) continue to face stark inequalities in care. It’s time to ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Sanofi is scheduled to report results for ... Its anti-inflammatory drug Dupixent was scheduled for review in April, and its multiple sclerosis drug tolebrutinib in September, UBS analysts said ...

As sure as the sun rises, prescription medicine use and total drug spending continue to increase in the U.S. | Last year's ...

Sanofi’s tolebrutinib leads the race for FDA approval The BTK inhibitor for multiple sclerosis that is currently furthest ahead in the development pipeline is Sanofi’s tolebrutinib, an oral ...